Has Shalin Shakya, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,894 in general payments to Shalin Shakya, MD across 69 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Shalin Shakya, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Shalin Shakya, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Shalin Shakya, MD

Hospitalist · Cypress, TXNPI 1548573173

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 69 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Paratek Pharmaceuticals, Inc. at 36.5% of the total. Reporting peaked in 2021 at $1,298 and has fallen 79.4% since, to $268 in 2025. Among hospitalist clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,894in general payments, 2019–2025

Across 69 payments — averaging $41.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Paratek Pharmaceuticals, Inc.$1K
AstraZeneca$686
Johnson & Johnson$317
La Jolla Pharmaceutical Company$212
Madrigal Pharmaceuticals$136
BETA Bionics, Inc.$132
plus $355 from 8 others

What the payments were for

Food & beverage$2,894100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Paratek Pharmaceuticals, Inc.	16	$1,056
AstraZeneca(2 entities)	15	$686
Johnson & Johnson	16	$317
La Jolla Pharmaceutical Company	2	$212
Madrigal Pharmaceuticals	1	$136
BETA Bionics, Inc.	1	$132
Novartis	7	$123
Melinta Therapeutics, LLC	1	$55
Vifor Pharma, Inc.	2	$47
AbbVie	3	$39
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	2	$27
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	1	$26
Takeda Pharmaceuticals U.S.A., Inc.	1	$19
Mylan Specialty L.p.	1	$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

NUZYRA$866
iLet Bionic Pancreas$395
LOKELMA$250
ANDEXXA$249
REZDIFFRA$136
iLet Insulin Infusion Kit Inset$132
iLet Insulin Infusion Kit Contact Detach$132
Xerava$118

How this compares

$2,894 in reported general payments places this provider in the 95th percentile of 1,284 hospitalist providers in Texas.

See all hospitalist providers in Texas →

Medicare billing

Part B allowed, 2024

$67,484

Medicare patients

273

Services billed

635

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	13	$8,750
Pantoprazole Sodium	22	$373
Cefdinir	36	$293
Albuterol Sulfate HfaAlbuterol Sulfate	12	$164
Metoprolol Succinate	25	$163
Amiodarone Hcl	11	$108
Methylprednisolone	12	$89
Atorvastatin Calcium	19	$86
Lisinopril	14	$62
ClopidogrelClopidogrel Bisulfate	12	$58
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	13	$58
Tamsulosin Hcl	11	$42
Furosemide	17	$35

Paid to pharmacies, not to this prescriber.

Other hospitalist in Cypress

Kenechukwu EnekebeCorpus Christi$311K
Ryan NealHouston$154K
Sarah SmileyAustin$90K
Mubeen CheemaSan Antonio$50K
Ahmad BaroutHouston$44K
Tarek HammadSan Antonio$42K
Hendre FichardtSan Antonio$36K
Sadie Trammell VelasquezSan Antonio$36K
Weiyi TanDallas$30K
Laxman KalvakuntlaHouston$30K

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →